Octave Bioscience

Blood biomarkers that reveal hidden MS disease

Menlo Park, California, United States

Other Diagnostics & Monitoring Molecular Diagnostics Neurology Precision Medicine/DiagnosticsSeries C

Octave Bioscience is a precision care company that offers a biomarker-driven testing platform to provide objective insights for monitoring and treating neurodegenerative diseases.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Octave Bioscience on @MedStartr Today Octave Bioscience is a precision care company that offers a biomarker-driven testing platform to provide objective insights for monitoring and treating neurodegenerative diseases. #NeurodegenerativeDiseases #ParkinsonSDisease #AlzheimerSDiseaseDementia #MultipleSclerosis #Other #DiagnosticsScreeningMonitoring #MolecularDiagnostics #Neurology #PrecisionMedicineDiagnostics #MedMo #MedStartrVentures

https://www.medstartr.ai/s/wQ0BbHkPAZI

Note, this image was autogenerated by Syggy based on what we know about the company. It is not an official company publication.

Get Involved in Octave Bioscience

1 engagement

How We Help

Problem Statement

The company addresses the challenge of monitoring and making treatment decisions for neurodegenerative diseases by providing objective, data-driven insights into disease activity.

Core Technology

Biomarker Testing & AI

Key Differentiators

First-of-its-kind multi-analyte blood test for Multiple Sclerosis (MS) disease activity.; Combines biomarker testing with artificial intelligence to provide clinically actionable insights.

Clinical Focus

Neurology

Company Info

Business Model: B2B
Founded: 2014
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: www.octavebio.com/

Disease Areas

Neurodegenerative Diseases Parkinson's Disease Alzheimer's & Dementia Multiple Sclerosis

Technologies

BiomarkersDiagnostic TestingAnalytics & BIPrecision Medicine TechAI & Machine Learning

Clinical & IP

🔬

Clinical Validation

18-protein MSDA Test validated in Nature Communications (2024), Proteomics Clinical Applications (2023), and Clinical Immunology (2023). CLIA-certified, NY State CLEP-certified. Real-world data: 19.4% of clinician decisions changed post-test; patients with high MSDA scores 4x+ more likely to have inflamed lesions.

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Octave Bioscience?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.